Japan-based Fujifilm Corporation has announced the investment of $1.6 billion to enhance and expand the cell culture manufacturing services of Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm Corporation, and world-leading contract development and manufacturing organization (CDMO). This investment will enhance Fujifilm Diosynth Biotechnologies’ sites in Hillerød, Denmark, and Texas in the United States.
As part of this investment, Fujifilm Diosynth Biotechnologies is further expanding its capacity to support large-scale cGMP fed batch production by adding 8 x 20,000L bioreactors and two downstream processing streams in its Hillerød, Denmark facility.
The additional production capacity will make the Hillerød facility the largest end-to-end CDMO in Europe, offering a total of 20 x 20,000L bioreactors for drug substance production complimented by comprehensive drug product and finished goods services. The investment is expected to create approximately 450 jobs.
The Denmark facility will be enhanced with sustainability measures to support Fujifilm’s new “Green Value Climate Strategy” with climate action targets including operating on carbon-free energy and achieving net zero CO2 emissions by the end of Fiscal Year 2040.
This investment will also expand cell culture manufacturing solutions at the Fujifilm Diosynth Biotechnologies’ Texas site. The company will implement its proprietary SymphonX production equipment, enabling cGMP MaruX continuous processing at the single-use cell culture manufacturing site.